ArticleCancer epidemiology2025
Cancer in persons diagnosed with facial nerve paresis: A hospital-based cohort study in Denmark.
Article in Cancer epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeoplasms can compress or infiltrate the facial nerve, leading to facial nerve paresis or palsy (FNP). As evidence regarding cancers outside the head, neck, and nervous system in persons initially diagnosed with FNP remains limited, we examined the overall and site-specific cancer rates among all patients diagnosed with FNP in Denmark over a 29-year study period.
methodsWe conducted a hospital-based cohort study in Denmark, 1994-2022, identifying FNP from inpatient, outpatient, or emergency room visits. We computed absolute risks (AR), and age- and sex-standardized incidence ratios (SIR) with corresponding 95 % confidence intervals (CIs) for all cancers, cancer groups, and site-specific cancers diagnosed <1 year and ≥1 after FNP diagnosis.
resultsThere were 27,147 recorded diagnoses of FNP. For cancers diagnosed <1 year after FNP, the AR was 1.67 % (95 %CI: 1.53,1.83) and the SIR was 2.62 (95 %CI: 2.38,2.87) with strong associations for cancers of the nervous system (SIR=14.7, 95 %CI: 12.1,17.7) and head and neck (SIR = 8.37, 95 %CI: 6.41,10.7). For cancers diagnosed ≥1 year after FNP, the AR was 20.2 % (95 %CI: 18.0,22.6) and the SIR was 1.08 (95 %CI: 1.04,1.13) with persistent associations for cancers of the salivary gland (SIR=2.43, 95 %CI: 1.11,4.62), brain (SIR = 1.48, 95 %CI: 1.16,1.86), spinal cord, cranial nerves, and other parts of the central nervous system (SIR = 1.83, 95 %CI: 1.22,2.62), liver (SIR = 2.02, 95 %CI: 1.50,2.65), and anus (SIR = 1.94, 95 %CI: 1.09,3.20).
conclusionRates of local cancers remained persistently elevated among persons diagnosed with FNP as compared with the Danish general population, as did rates of distant cancers implying a key role for metastatic disease as an underlying cause of FNP. Research that explores these associations by cancer stage may yield additional insight into these observed associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.